Journal article Open Access

ARE DMARDS BENEFICIAL IN MANAGEMENT OF PSORIASIS?

Rania Sami Iraqi


MARC21 XML Export

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <controlfield tag="005">20220729014927.0</controlfield>
  <controlfield tag="001">6927082</controlfield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="s">896392</subfield>
    <subfield code="z">md5:c0e08468284e47c597837721de11131e</subfield>
    <subfield code="u">https://zenodo.org/record/6927082/files/61.Psoriasis DMARDs.pdf</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2022-07-28</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="p">openaire</subfield>
    <subfield code="o">oai:zenodo.org:6927082</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Rania Sami Iraqi</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">ARE DMARDS BENEFICIAL IN MANAGEMENT OF PSORIASIS?</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="u">https://creativecommons.org/licenses/by/4.0/legalcode</subfield>
    <subfield code="a">Creative Commons Attribution 4.0 International</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="a">cc-by</subfield>
    <subfield code="2">opendefinition.org</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">&lt;p&gt;&lt;strong&gt;&lt;em&gt;Introduction:&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;Psoriasis is a chronic inflammatory papulosquamous skin disease with genetic predisposition and autoimmune pathogenicity. Psoriasis may also affect the joints as psoriatic arthritis and may even be associated with other conditions. Research into the pathogenesis of Psoriasis in the last few decades has given rise to several targeted therapies. Among them are Disease-modifying anti-rheumatic drugs (DMARDs), mainly used in cases of psoriatic arthritis. The article will review the various disease-modifying anti-rheumatic drugs along with strengths and weaknesses in combating Psoriasis. &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;em&gt;The aim of work&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;: An overview is aimed at describing various DMARDs and their use against Psoriasis.&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;em&gt;Methodology: &lt;/em&gt;&lt;/strong&gt;&lt;em&gt;The review is a thorough review of PUBMED articles from the year 1984 to 2019 relating to DMARDs and Psoriasis.&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;em&gt;Conclusion:&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;Psoriasis is a chronic inflammatory skin disease that also affects other systems of the body due to inflammation. DMARDs are a group of drugs that are used to combat Psoriasis and various other inflammatory ailments. This review briefly discusses the most common examples of DMARDs, their mechanism of action, efficacy in trials, and adverse effects. &lt;/em&gt;&lt;/p&gt;</subfield>
  </datafield>
  <datafield tag="773" ind1=" " ind2=" ">
    <subfield code="n">doi</subfield>
    <subfield code="i">isVersionOf</subfield>
    <subfield code="a">10.5281/zenodo.6927081</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.5281/zenodo.6927082</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
</record>
10
11
views
downloads
All versions This version
Views 1010
Downloads 1111
Data volume 9.9 MB9.9 MB
Unique views 1010
Unique downloads 1111

Share

Cite as